Symptoms (when taking the drug in a dose of more than 5 tablets.): signs of intoxication in the form of drowsiness; in children - anxiety, increased irritability, the appearance of signs of anticholinergic action in the form of a delay in urine, dry mouth, constipation.
Treatment: taking the drug should be stopped, peeled, take activated carbon, immediately consult a doctor.
Increased sensitivity to cetyrizin, other components of the drug, hydroxysine.
Usually the drug is well tolerated. In some cases, headache, drowsiness, dizziness, excitation, dry mouth are possible; disorders from the gastrointestinal tract: dyspepsia, abdominal pain, meteorism. As an exception, signs of hypersensitivity to the drug (short, swelling, shortness of breath) are possible. In this case, treatment with the drug should be stopped immediately and an urgent appeal to the doctor. It is necessary to inform the doctor about all side (unusual) effects.
Uncounter.
treatment of symptoms of year-round and seasonal allergic rhinitis and allergic conjunctivitis (such as itching, sneezing, nose congestion, rhinorea, lacrimation, conjunctiva hypermia);
hay fever (flaymaking) ;
urticaria;
allergic dermatoses, including.h. atopic dermatitis, accompanied by itching and rashes.
It is shown in adults and children with 6 months and older to facilitate :
- nasal and eye symptoms of year-round (persisting) and seasonal (intermittent) allergic rhinitis and allergic conjunctivitis: itching, sneezing, nasal congestion, rhinorea, tearing, conjunctival hyperemia ;
- symptoms of chronic idiopathic urticaria.
Symptomatic treatment of allergic rhinitis and conjunctivitis (including year-round and seasonal), hay fever (pollinosis), idiopathic urticaria and other allergic dermatoses, accompanied by itching and rashes.
Symptomatic treatment of allergic rhinitis and conjunctivitis (including year-round and seasonal), hay fever (pollinosis), idiopathic urticaria and other allergic dermatoses, accompanied by itching and rashes.
Keep out of the reach of children.
Shelf life of the drug Parlasin®tablets covered with a film shell of 10 mg - 4 years.
drops for admission inside 10 mg / ml - 4 years. Open bottle store no more than 4 weeks.
Do not apply after the expiration date indicated on the package.
| Drops for taking in | 1 fl./ 1 ml |
| active substance : | |
| cetirizina dihydrochloride | 0.2 g / 10 mg |
| auxiliary substances : glycerol - 5 g / 250 mg; propylene glycol - 7 g / 350 mg; sodium sakharinate - 0.2 g / 10 mg; sodium acetate trihydrate - 0.2 g / 10 mg; methylparagidroxybenzene - 0.027 g / apil.35 mg |
| Tablets coated with a film shell | 1 table. |
| active substance : | |
| cetirizina dihydrochloride | 10 mg |
| auxiliary substances : silicon dioxide colloidal; magnesium stearat; lactose monogydrate; MCC | |
| film shell : Opadry Y-1-7000 ; Ariavit, Sunset yellow C.I. 15985 (colored by Sunset yellow) |
Drops for taking inward, 10 mg / ml. For 20 ml of the drug in a bottle of brown glass with a PE-camera and a polypropylene lid with an internal PE layer, with control of the first autopsy, as well as with protection against opening by children. 1 bottle in a cardboard pack.
Tablets coated with a film shell, 10 mg. 5, 7 or 10 tablets each. in PVC / PVDH / aluminum foil blisters. 1 blister (5, 7 or 10 tablets each.) or 3 blisters (10 tablets each.) in a cardboard pack.
Inside.
Drops dissolve in a small amount of water before taking.
Adults and adolescents over 12 years old: 10 mg (20 drops or 1 table.) once a day, preferably at night.
Children aged 6–12 years: 5 mg each (10 drops or 1/2 table.) 2 times a day (morning and evening) or 10 mg (20 drops or 1 whole tablet) in the evening.
Children aged 1-6 years It is recommended to appoint Parlasin® in the medicinal form of a drop for taking in.
Children aged 2–6 years: 5 mg (10 drops per day) once. You can also divide this dose by 2 doses of 2.5 mg (5 drops in the morning and evening).
Children aged 1-2 years: 2.5 mg (5 drops) 2 times a day.
Special patient groups
It may be necessary to reduce the dose of y elderly patients.
At kidney function violation the dose should be set individually, in accordance with the function of the kidneys. The table below will assist in the selection of doses. To use this table, you should evaluate Cl creatinine in a patient in ml / min. After determining the concentration of creatinine of blood serum (mg / dl), the value of Cl creatinine can be estimated using the following formula:
Cl creatinine = [(140 − age, years) × body weight, kg) / (72 − creatinine blood serum, mg / dl]
When calculating creatinine clearance for women, the result must be multiplied by 0.85. The table shows the doses depending on Cl creatinine.
Table
The dose selection depending on the clearance of creatinine
| Cl creatinine, ml / min | Dosage |
| ≥80 | 10 mg 1 time per day |
| 50–79 | 10 mg 1 time per day |
| 30–49 | 5 mg 1 time per day |
| 11–29 | 5 mg 1 time in 2 days |
| ≤10 (hemodialysis) | contraindicated |
